143 related articles for article (PubMed ID: 3622314)
1. Experience of long term treatment and different dosage regimens of isosorbide 5-mononitrate.
Meffert M; Paeckelmann IM
Drugs; 1987; 33 Suppl 4():104-10. PubMed ID: 3622314
[TBL] [Abstract][Full Text] [Related]
2. Long term efficacy of a controlled-release formulation of isosorbide 5-mononitrate (Imdur) in angina patients receiving beta-blockers.
Uusitalo A
Drugs; 1987; 33 Suppl 4():111-7. PubMed ID: 2887418
[TBL] [Abstract][Full Text] [Related]
3. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
Gunasekara NS; Noble S
Drugs; 1999 Feb; 57(2):261-77. PubMed ID: 10188765
[TBL] [Abstract][Full Text] [Related]
4. Randomized crossover trial of isosorbide mononitrate (Elantan 20) and slow-release glyceryl trinitrate in the treatment of angina pectoris.
Brodie NH; O'Hara H; O'Hara J; Valle-Jones JC
Pharmatherapeutica; 1985; 4(6):367-75. PubMed ID: 3936056
[TBL] [Abstract][Full Text] [Related]
5. Abrupt withdrawal of isosorbide 5-mononitrate (Imdur) after long term treatment in stable angina pectoris. A preliminary report.
Rehnqvist N; Olsson G; Engvall J; Rosenqvist U; Nyberg G; Aberg A; Ulvenstam G; Uusitalo A; Keyriläinen O; Härkönen R
Drugs; 1987; 33 Suppl 4():118-21. PubMed ID: 2887419
[TBL] [Abstract][Full Text] [Related]
6. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
Parker JO
Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
[TBL] [Abstract][Full Text] [Related]
7. [Selection of therapy with nitrates in patients with stable effort angina: results of comparative study of common isosorbide dinitrate and long acting preparation of isosorbide-5-mononitrate].
Martsevich SIu; Semenova IuE; Alimova EV; Dmitrieva nA; Kozyreva MP; Koniakhina IP; Lukina IuV; Egorov VA
Kardiologiia; 2005; 45(11):42-5. PubMed ID: 16353064
[TBL] [Abstract][Full Text] [Related]
8. Abrupt withdrawal of isosorbide-5-mononitrate in Durules (Imdur) after long term treatment in patients with stable angina pectoris.
Rehnqvist N; Olsson G; Engvall J; Rosenqvist U; Nyberg G; Aberg A; Ulvenstam G; Uusitalo A; Keyriläinen O; Reinikainen P
Eur Heart J; 1988 Dec; 9(12):1339-47. PubMed ID: 3147892
[TBL] [Abstract][Full Text] [Related]
9. A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina.
Walker JM; Curry PV; Bailey AE; Steare SE
Int J Cardiol; 1996 Feb; 53(2):117-26. PubMed ID: 8682597
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris.
Seabra-Gomes R; Aleixo AM; Adao M; Machado FP; Mendes M; Bruges G; Palos JL
Am J Cardiol; 1990 Jun; 65(20):1308-12. PubMed ID: 2188493
[TBL] [Abstract][Full Text] [Related]
11. Long-acting isosorbide mononitrate.
Prakash A; Markham A
Drugs; 1999 Jan; 57(1):93-9; discussion 100. PubMed ID: 9951954
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with Imdur in angina pectoris. A review.
Nyberg G
Eur J Clin Pharmacol; 1990; 38 Suppl 1():S65-8. PubMed ID: 1972359
[TBL] [Abstract][Full Text] [Related]
13. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
Thadani U
Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
[TBL] [Abstract][Full Text] [Related]
14. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
[TBL] [Abstract][Full Text] [Related]
15. Long-term therapeutic efficacy with once-daily isosorbide-5-mononitrate (Imdur).
Kendall MJ
J Clin Pharm Ther; 1990 Jun; 15(3):169-85. PubMed ID: 2195051
[No Abstract] [Full Text] [Related]
16. Anti-ischemic and anti-anginal effects of controlled-release and conventional isosorbide-5-mononitrate in stable angina pectoris.
Chen YH; Ding PY; Wang SP
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Oct; 61(10):577-83. PubMed ID: 9830234
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
Chrysant SG; Glasser SP; Bittar N; Shahidi FE; Danisa K; Ibrahim R; Watts LE; Garutti RJ; Ferraresi R; Casareto R
Am J Cardiol; 1993 Dec; 72(17):1249-56. PubMed ID: 8256699
[TBL] [Abstract][Full Text] [Related]
18. Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary heart disease: a multi-centre study.
Bidoggia H
Curr Med Res Opin; 1987; 10(9):601-11. PubMed ID: 3325229
[TBL] [Abstract][Full Text] [Related]
19. Anti-anginal efficacy of a controlled-release formulation of isosorbide-5-mononitrate once daily in angina patients on chronic beta-blockade.
Uusitalo A; Keyriläinen O; Härkönen R; Rautio P; Rehnqvist N; Engvall J; Rosenqvist U; Nyberg G; Aberg A; Ulvenstam G
Acta Med Scand; 1988; 223(3):219-25. PubMed ID: 2895564
[TBL] [Abstract][Full Text] [Related]
20. An open, long-term, multi-centre study of the anti-anginal efficacy and safety of isosorbide 5-mononitrate at low doses in patients with coronary heart disease.
Uberbacher HJ; Steinorth G; Glocke M; Abshagen U
Pharmatherapeutica; 1983; 3(5):331-41. PubMed ID: 6342004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
